You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Controversies Accelerated Drug Development Through Combined Phase 2/3 Clinical Trial Design
Emmett T. Cunningham Jr; Loni da Silva; Evelyn M. Harrison; Marlene W. Modi; Denis O'Shaughnessy; David R. Guyer
Arch Ophthalmol 2004; 122: 1043-1044.
[Extract][Full text][PDF]
Clinical Sciences Use of Best and Final Visual Acuity Outcomes in Ophthalmological Research
David A. DiLoreto Jr; Neil M. Bressler; Susan B. Bressler; Andrew P. Schachat
Arch Ophthalmol 2003; 121: 1586-1590.
[Abstract][Full text][PDF]
Clinical Sciences Consistency Between Visual Acuity Scores Obtained at Different Test Distances: Theory vs Observations in Multiple Studies
Li Ming Dong; Barbara S. Hawkins; Marta J. Marsh
Arch Ophthalmol 2002; 120: 1523-1533.
[Abstract][Full text][PDF]
Clinical Sciences Reproducibility of Retinal Mapping Using Optical Coherence Tomography
Pascale Massin; Eric Vicaut; Belkacem Haouchine; Ali Erginay; Michel Paques; Alain Gaudric
Arch Ophthalmol 2001; 119: 1135-1142.
[Abstract][Full text][PDF]
Clinical Sciences Validity of the Visual Function Index (VF-14) in Patients With Retinal Disease
Mark Linder; Tom S. Chang; Ingrid U. Scott; Dawn Hay; Keith Chambers; Lyn M. Sibley; Ezekiel Weis
Arch Ophthalmol 1999; 117: 1611-1616.
[Abstract][Full text][PDF]
Commentaries The CONSORT Statement: Will It Lead to Improved Reporting of Clinical Trials in Ophthalmology?
